Welcome to our dedicated page for Innovate news (Ticker: VATE), a resource for investors and traders seeking the latest updates and insights on Innovate stock.
INNOVATE Corp. (NYSE: VATE) generates news across its three reported segments: Infrastructure, Life Sciences and Spectrum. As a holding company with operating subsidiaries and equity method investments, its disclosures cover developments in structural steel construction, medical technology, aesthetic devices and over-the-air broadcasting.
News about the Infrastructure segment often focuses on DBM Global Inc., a family of companies providing integrated steel construction services. Coverage includes project activity, revenue by segment, backlog levels and cash dividends paid by DBM Global to its stockholders, with INNOVATE identified as the largest stockholder.
In Life Sciences, INNOVATE’s news highlights regulatory and commercial milestones at portfolio companies such as MediBeacon Inc. and R2 Technologies, Inc. Releases have detailed U.S. Food and Drug Administration approval for MediBeacon’s TGFR system, approvals in China for the Transdermal GFR System and Lumitrace injection, and growth in R2’s Glacial Skin CryoAesthetics platforms and global system sales.
The Spectrum segment generates updates on broadcasting operations, including revenue trends, new network launches and datacasting initiatives using ATSC 3.0 technology. INNOVATE has reported on the launch of ATSC 3.0 stations for a large mobile carrier and efforts to expand reach with additional networks.
Investors and followers of VATE can use this news feed to review INNOVATE’s quarterly earnings releases, Form 8-K announcements, refinancing transactions, segment performance commentary and major events at DBM Global, MediBeacon and R2. Regular updates provide a consolidated view of how developments in each segment contribute to the overall INNOVATE portfolio.
INNOVATE (NYSE: VATE) said DBM Global Inc., its operating subsidiary, will pay a $3.0 million cash dividend (about $0.78 per share) on April 28, 2026 to stockholders of record as of April 13, 2026.
INNOVATE, as DBMG’s largest stockholder, expects to receive ~$2.7 million; INNOVATE individual stockholders are not eligible for the payout.
INNOVATE (NYSE: VATE) said MediBeacon, an equity-method investment, received EU CE Mark under MDR for its TGFR Monitor and TGFR Reusable Sensor (both Class IIa).
The certified devices join the CE marked TGFR Disposable Ring and Lumitrace injection (approved in U.S. and China; EU submission pending) to form the TGFR System for transdermal GFR assessment, enabling potential inclusion in European clinical trials later in 2026.
INNOVATE (NYSE: VATE) reported fourth-quarter and full-year 2025 results on March 26, 2026. Q4 revenue was $382.7M (+61.7% YoY) and FY2025 revenue was $1,246.0M (+12.5% YoY). Q4 net loss attributable to common stockholders was $7.8M (loss per share $0.58). Total Adjusted EBITDA for Q4 was $24.5M. Infrastructure backlog expanded to $1.8B. Cash and equivalents were $112.1M at year-end.
Highlights included DBMG margin compression, FDA approval and MediBeacon commercialization steps, a 600‑system China commitment for R2, and Spectrum ad softness with expected 2026 benefits.
INNOVATE Corp (NYSE: VATE) will report its fourth quarter and full year 2025 results on March 26, 2026 after market close. A live earnings conference call will follow at 4:30 p.m. ET the same day and will be webcast on the company Investor Relations website.
Dial-in and replay details are provided for domestic and international participants; a replay will be available through April 9, 2026.
INNOVATE (NYSE: VATE) holds a 44.7% equity interest in MediBeacon, whose transdermal GFR (TGFR) article was named one of five 2025 JASN Editor’s Choice articles and was the August 2025 JASN cover feature. Centers of Excellence commercialization of the MediBeacon Transdermal GFR System began in January 2026.
The TGFR System uses Lumitrace (relmapirazin) injection, a monitor and reusable sensor to provide a point-of-care transdermal measurement of glomerular filtration rate, targeted initially at heart failure monitoring, transplant evaluation and oncology drug dosing.
INNOVATE (NYSE: VATE) said DBM Global Inc., its operating subsidiary, will pay a $5.0 million cash dividend (about $1.30 per share) on Feb 24, 2026 to stockholders of record as of Feb 9, 2026. INNOVATE, as DBMG’s largest stockholder, expects to receive roughly $4.6 million of the payout. Individual INNOVATE shareholders are not eligible for this dividend.
INNOVATE (NYSE:VATE) holds a 44.7% equity interest in MediBeacon, which received FDA approval on December 16, 2025 for the next‑generation MediBeacon® TGFR™ System including the new TGFR Reusable Sensor.
The TGFR System measures clearance of Lumitrace® (relmapirazin) transdermally to assess kidney function at the point of care. The reusable sensor is designed for patient comfort, reusability via a disposable adhesive ring, and lower cost versus the previously approved single‑use sensor. MediBeacon highlighted a lead JASN cover article (August 2025) and cites >700 preclinical publications. Early access commercialization at select academic medical centers in the US and China is expected to begin in Q1 2026.
INNOVATE Corp (NYSE: VATE) reported third quarter 2025 consolidated revenue of $347.1M, up 43.3% year-over-year, driven by Infrastructure growth. Total Adjusted EBITDA was $19.8M, up 17.9% year-over-year. Net loss attributable to common stockholders narrowed to $9.4M (loss per share $0.71).
Key operational items: DBM Global revenue rose to $338.4M (+45.4%) with adjusted backlog of $1.6B. MediBeacon received NMPA approval to sell the Transdermal GFR System in China and expects sales before year-end. The company completed refinancing transactions but missed milestone dates, triggering sales/strategic processes for DBMG and HC2 Broadcasting.
INNOVATE Corp (NYSE: VATE) will release its third quarter 2025 financial results on Wednesday, November 12, 2025 after market close. The company will host an earnings conference call the same day starting at 4:30 p.m. ET to review results, operations and strategy.
The call will be broadcast live on INNOVATE’s Investor Relations website at www.innovate-ir.com; listeners should visit the Investor Relations section at least 15 minutes early to register. A replay will be available approximately three hours after the call and remain accessible through November 26, 2025. Domestic and international dial-in numbers and conference/replay details are provided for live and replay access.
INNOVATE (NYSE: VATE) announced that MediBeacon received NMPA approval for Lumitrace (relmapirazin) injection, the fluorescent agent used with the MediBeacon Transdermal GFR System (TGFR).
The TGFR—comprised of Lumitrace injection, the TGFR Monitor and TGFR Sensor—will be available for sale in China before the end of the year. The company noted prior approvals: the MediBeacon TGFR including Lumitrace received FDA approval in January, and NMPA previously approved the TGFR Monitor and Sensor in February. MediBeacon formed a commercial and clinical partnership with Huadong Medicine in July 2019. The release highlights tGFR as a point-of-care measured GFR alternative to lab-based eGFR and mGFR, and cites China CKD prevalence at 11% of 1.4 billion.